Please login to the form below

Not currently logged in
Email:
Password:

Kazano

This page shows the latest Kazano news and features for those working in and with pharma, biotech and healthcare.

FDA investigates pancreas risk of diabetes drugs

FDA investigates pancreas risk of diabetes drugs

Newer DPP-4 inhibitors Tradjenta (linagliptin) from Boehringer Ingelheim and Takeda's alogliptin-based medicines (Nesina, Kazano and Oseni) are also affected.

Latest news

  • Takeda gets FDA approval for alogliptin franchise in diabetes Takeda gets FDA approval for alogliptin franchise in diabetes

    Takeda gets FDA approval for alogliptin franchise in diabetes. Comprises Nesina, Oseni and Kazano. ... The US agency approved Takeda's DPP-4 inhibitor Nesina (alogliptin) - along with two fixed-dose combination products Oseni (alogliptin and pioglitazone)

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics